Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Thrombolytic Therapy for Acute Central Retinal Artery Occlusion
Stroke 51:687-695, Mac Grory, B.,et al, 2020
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Chemotherapy-Associated Hyperammonemic Encephalopathy
Neurol 94:e874-e877, Briard, J.N.,et al, 2020
Melbourne Mobile Stroke Unit and Reperfusion Therapy
Stroke 51:922-930, Zhao, H.,et al, 2020
Machine Learning Approach to Identify Stroke Within 4.5 Hours
Stroke 51:860-866, Lee, H.,et al, 2020
Management and Outcome of Primary CNS Lymphoma in the Modern Era
Neurol 94:e1027-e1039, Houillier, C., et al, 2020
Functional Neurological Disorder
Stroke 51:1629-1635, Popkirov, S., et al, 2020
Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke
Stroke 51:1616-1619, Beharry, J.,et al, 2020
Clinical and Radiologic Features of Pedicatric Opioid Use-Associated Neurotoxicity with Cerebellar Edema (POUNCE) Syndrome
Neurol 94:710-712, Kim, D.D. & Prasad, A.N., 2020
"CHOICES": An Acronym to Aid in Delineating Potential Causes of Non-Metabolic, Non-Infectious Acute Toxic Leukoencephalopathy
EJR OPEN 6:243-257, Koksel, Y.,et al, 2019
Toxoplasmosis in HIV-Infected Patients
www.UptoDate.com, May, Gandhi, R.T., 2019
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
NEJM 381:614-625, Pittock, S.J.,et al, 2019
Cytotoxic Lesions of the Corpus Callosum Caused by Thermogenic Dietary Supplements
AJNR 40:1304-1308, Galnares-Olalde, J.A.,et al, 2019
Pes Cavus and Neuropathy
Neurol 93:e823-e826, Alderson,J.,& Ghosh,P.S., 2019
Dupuytren, Ledderhose, and Peyronie Diseases after Primidone Use for Essential Tremor
Neurologist 24:150-151, Felipe, L.,et al, 2019
Neurolymphomatosis
Neurol 93:e1229-e1230, DeBoer, S.R.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Systemic Review of Malpractice Litigation in the Diagnosis and Treatment of Acute Stroke
Stroke 50:2858-2864, Haslett, J.J.,et al, 2019
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
Vaccine-Preventable Infections and Immunization in Multiple Sclerosis
Neurol 93:584-594, Farez, M.F.,et al, 2019
Clinicopathologic Conference, Adenovirus Meningoencephalitis
NEJM 381:1459-1470, Case 31-2019, 2019
Impact of Microbleeds on Outcome Following Recanalization in Patients with Acute Ischemic Stroke
Stroke 50:127-134, Choi, K.H.,et al, 2019
The Dangers of PRES
Neurol 92:e282-e285, Chaterine, C.,et al, 2019
Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA 32:175-187, Brown, J.W.L.,et al, 2019
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Peripheral Neuropathy Associated with Silver Toxicity
Neurol 92:481-483, Naddaf, E.,et al, 2019
Thrombus Length Predicts Lack of Post-Thrombolysis Early Recanalization in Minor Stroke With Large Vessel Occlusion
Stroke 50:761-764, Seners, P.,et al, 2019
Acute Toxic Limbic Encephalopathy Following Glyphosate Intoxication
Neurol 92:534-536, Planche, V.,et al, 2019
Acute Toxic Leukoencephalopathy: Etiologies, Imaging Findings, and Outcomes in 101 Patients
AJNR 40:267-275, Ozutemiz, C.,et al, 2019
Bismuth Neurotoxicity from Use of Topical Bismuth Dressing for Burns
Neurol 92:680-681, Saini, V.,et al, 2019
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
A Woman in her 40s with Transient Neurological Symptoms, Migraine Headaches, and Hearing Loss
JAMA Neurol 76:504-505, Roshal, D.A.,et al, 2019
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
NEJM 380:1597-1605, Cortese, I.,et al, 2019
Clinicopathologic Conference, Ingestion of Isopropyl Alcohol
NEJM 380:1657-1665, Case 13-2019, 2019
Magnetic Resonance Imaging Versus Computed Tomography Angiography Based Selection for Endovascular Therapy in Patients with Acute Ischemic Stroke
Stroke 50:365-372, Kim, J-T.,et al, 2019
Cholesterol Lowering and Prevention of Stroke
Stroke 50:537-541, Hackam, D.G. & Hegele, R.A., 2019
Simultaneous CMV and Listeria Infection Following Alemtuzumab Treatment for Multiple Sclerosis
Neurol 92:296-298, Pappolla, A.,et al, 2019
Acute Encephalitis in Immunocompetent Adults
Lancet 393:702-716, Venkatesan, A.,et al, 2019
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
NEJM 380:1795-1803,1865, Ma, H.,et al, 2019
Recommendations for the Establishment of Stroke Systems of Care
Stroke 50:e1-e24, Adeoye, O.,et al, 2019
Imaging Findings After Mechanical Thrombectomy in Acute Ischemic Stroke
Stroke 50:1618-1625, Puntonet, J.,et al, 2019
Delayed Complications of Cranial Irradiation
www.UptoDate.com, May, Dietrich, J.,et al, 2019
Penumbra Detection in Acute Stroke with Perfusion Magnetic Resonance Imaging: Validation with 15 O-Positron Emission Tomography
Ann Neurol 85:875-886, Zaro-Weber, O.,et al, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019
Extending Thrombolysis to 4.5-9 h and Wake-Up Stroke Using Perfusion Imaging: A Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 394:139-147,97, Campbell, B.C.V.,et al, 2019
Clinicopathologic Conference, Statin-Associated Autoimmune Myopathy
NEJM 381:275-283, Case 22-2019, 2019
Clinical Characteristics and Treatment Outcomes for Patients Infected with Mycobacterium haemophilum
Emerg Inf Dis 25:1648-1652, Nookeu,P.,et al, 2019
Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial
Lancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019